26 reports of this reaction
5.8% of all MANGANESE SULFATE reports
#1 most reported adverse reaction
THROMBOCYTOPENIA is the #1 most commonly reported adverse reaction for MANGANESE SULFATE, manufactured by BM Private Limited. There are 26 FDA adverse event reports linking MANGANESE SULFATE to THROMBOCYTOPENIA. This represents approximately 5.8% of all 450 adverse event reports for this drug.
Patients taking MANGANESE SULFATE who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is moderately reported among MANGANESE SULFATE users, representing a notable but not dominant share of adverse events.
In addition to thrombocytopenia, the following adverse reactions have been reported for MANGANESE SULFATE:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 26 FDA reports for MANGANESE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 5.8% of all adverse event reports for MANGANESE SULFATE, making it one of the most commonly reported side effect.
If you experience thrombocytopenia while taking MANGANESE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.